PWR: This high flyer hits speed humps
I last wrote about PWR Holdings (ASX:PWH) over 18 months ago. It has been a bumpy ride since. At the time the share price was $8.60. It rose to $12.98 in February 2024 before halving to $6.10 in November. At the time of writing it is $7.80. So why the roller coaster?
At the time of the previous article, I referred to a screen built by Stockopedia contributor Roland Head that identifies quality stocks that are strong compounders. (Building a screen to find Compounding Quality stocks). PWR met the criteria for this screen at the time. It still does.
Criteria | Threshold | PWH Jun 23 | PWH Jan 25 |
QualityRank | 80 | 92 | 96 |
Long-term ROCE | 18% | 31.5% | 30.7% |
TTM ROCE | 15% | 30.2% | 30.0% |
Operating margin 5 yr avg | 10% | 28.7% | 27.4% |
Operating margin TTM | 10% | 26.4% | 25.2% |
Net margin 5 yr avg | 8% | 20.9% | 19.6% |
Net margin TTM | 8% | 19.5% | 17.8% |
OCF / EPS | 0.8 | 0.9 | 1.3 |
Avg FCF (long term) / Assets | 8% | 14.6% | 13.8% |
Sales CAGR 5 yr | 0% | 16.0% | 16.3% |
Sales TTM / Sales Prior TTM | 5% | 23.5% | 17.8% |
Debt to assets | <50% | 16.7% | 11.4% |
Interest cover | 10x | 100x | 121x |
Whilst most metrics have declined marginally, it is still a very high quality stock as reflected in the Quality rank of 96 and the sales and profitability metrics continue to compound.
First some background. PWR is a manufacturer of advanced cooling systems. They have traditionally been focussed on motorsport and are the dominant provider of cooling systems for Formula 1 with all teams using their cooling products. They also work with Supercars, touring cars, rally cars, Nascar and Indycar teams all over the world.
Over recent years they have been diversifying their offerings, and now generate about half their revenue outside Motorsport, from supplying cooling solutions to car manufacturers (OEMs), the automotive aftermarket and aerospace and defence.
Source: PWR Holdings, FY2024 Annual Results Presentation, 15/8/24
The share price climbed strongly during the second half of 2023 on the back of record revenue and profit for the FY23 year as revealed in August 2023. This included strong revenue growth across each of the segments running from 12% for the Automotive aftermarket to 48% for Aerospace and defence. Importantly there was a lot of optimism about the outlook and a strong pipeline of OEM projects (building components for production cars) as well as Aerospace and defence projects and Motorsport. They were investing in a UK manufacturing facility to service the European market.
This optimism peaked leading into the release of the FY24 half year results in February 2024, and then slumped as reality failed to keep pace with the very lofty expectations. The headline numbers were still very good with revenue growth of 22% and profit growth of 26%. But digging into the details showed revenue growth in Automotive OEM of only 4%.
At the time, PWH had a very low value score, reflecting the fact that most metrics were at stratospheric levels. The growth expectations were particularly focussed on emerging technologies for OEMs and aerospace and defence, as the historical mainstay of the business, Motorsport, is always going to be a niche application. Once this growth rate was checked a little, expectations were reweighted and valuation multiples declined accordingly.
The next significant announcement was the release of the FY24 full year results in August. Again the headline was record revenue and record profits. Revenue growth tapered back to 18% indicating that growth in the second half was not as strong as the first half. Profit growth was 14% for the full year compared to 26% for the first half. These results fell short of market expectations and set off a further decline in the share price.
The biggest slump occurred in November when the company issued an earnings guidance downgrade. They forecast that net profit for the first half would fall between 62% and 67% when compared to the same period last year. This was driven by a revenue slump in two key segments, OEM and automotive aftermarket. Revenue from OEM is expected to fall 44% and aftermarket is forecast to decline 19%. The OEM slump is due to three niche EV programs not proceeding in FY25 due to volatility in the EV market. Aftermarket is suffering due to broad economic pressure. They are reducing costs to try and alleviate some of the pain.
Management has stated that FY25 is a transition year as they invest in new facilities and equipment in preparation for the expected increase in demand, especially in the aerospace and defence segment. Of course, if that demand failed to materialise the business would be left carrying increased overhead. EPS for FY25 is now forecast to decline 31%.
Most analysts are currently recommending the stock as HOLD or SELL. There was considerable disappointment following the downgrade although the stock rebounded somewhat from its initial decline. This negative sentiment has driven down the Momentum rank.
The Value score has increased but is still very low at 18. Historical and PE ratios are still above 30 and the price to sales ratio is 5.75. The Quality score remains high at 96. PWR remains a high quality business, but it is facing some hurdles. The road to victory is rarely straight. For those who have been waiting for an opportunity to get into this high quality stock, or to top up their holding, now may be that time. That said, there may be more speed bumps and volatility ahead. Whilst the price has certainly declined it is not yet at bargain levels.
Important Information: Stockopedia Ltd ABN 39 757 874 670 UK business registration number 0637267 (“Stockopedia”) is an Authorised Representative of Daylight Financial Group Pty Ltd ABN 77 633 984 773 (“DFGPL”) which is the holder of an Australian Financial Services Licence (AFS Licence No. 521404).
Information in this commentary is current as at date prepared unless otherwise stated. However, please bear in mind that investments can go up or down in value, and that past performance is not a reliable indicator of future performance. For more Important Information please refer to the Disclaimer section of this website.
This communication may contain general financial product advice. It has been prepared without taking into account your personal circumstances, and you should therefore consider its appropriateness in light of your objectives, financial circumstances and needs before acting on it.
If our advice relates to the acquisition or possible acquisition of a particular financial product, you should obtain a copy of and consider the Product Disclosure Statement (PDS) before making any decision.
The author holds interests in the following stocks mentioned in this article: PWH. This position can and will change at any time without notice.
Disclaimer
This is not financial advice. Our content is intended to be used and must be used for information and education purposes only. Please read our disclaimer and terms and conditions to understand our obligations.

15 comments
As an Australia / New Zealand subscriber there seems to be very little commentary on Australian stocks lately.
It seems they've closed shop down here :(
I've been an Australia / New Zealand subscriber for the last 2 - 3 months, yes whilst the quality of the data and information around Aussie stocks is fantastic its a shame there has been nothing significant in discussion or commentary so far this year. I've got a NAPS based portfolio I'm following and am plotting and planning articles perhaps to review it and talk about stock selection, I may start soon. It would be good though too to make contact with the aussie community here, get a discussion going and perhaps learn what different people are doing.
My screen throws up Aussie stocks every now and thenn. I'm currently up 39% on Genusplus (ASX:GNP) and 20% on Cogstate (ASX:CGS. Surprisingly neither are gold miners.
Hi Phil,
My NAPS portfolio is pretty balanced, like the one though that was commentated on in 2024 for AU/NZ I found a couple of weak sectors but I feel its still quite broad. I've found there a few excellent performers, Ricegrowers (ASX:SGLLV) and Data#3 (ASX:DTL) have done well. I've had an eye on Cogstate (ASX:CGS) but went with Sonic Healthcare (ASX:SHL) which fell off a cliff recently and is my worst performer, still don't fully understand what happened there.
Hi Francis, according to chatgpt (a great resource for checking this sort of thing) Sonic Healthcare (ASX:SHL) missed their earnings expectations
https://www.stockopedia.com/share-prices/sonic-healthcare-ASX:SHL/news/urn:newsml:reuters.com:20250821:nL6N3UD011
Hi Phil,
Fair enough. Yes, I do remember seeing this come to think of it but just didn't think it justified a 10%+ correction. There may be other factors at play that coincided: 1. it went ex-div; 2. There is a change in a key board member shortly.
What's your read of Cogstate?
Thanks,
Francis
Re: Profit Warnings ... you might want to take a look at this ...https://www.stockopedia.com/co...
Re: Cogstate ... erm I'm a quantative investor, basically I'm driven by my screening process. I know nothing about Cogstate apart from they are an Australian Heathcare company and to pass my screen (when I bought them) they must have ...
A high quality above 80
A QM score above 80
Limited debt and a strong balance sheet
Been making a profit
Have increasing EPS estimates
Been close to 52 week highs
I'll be talking to Ed about this approach in a webinar later this month.
Hi Phil,
Thanks for the link to the Profit Warnings report, I'll take a detailed look at it this week. I actually just published an article on my portfolio and mentioned it: https://www.stockopedia.com/co...
I'll also try your screen, build it myself and see perhaps, check what Aussie companies it throws up at the moment.
What's the webinar Ed is on this month, is there a link?
Thanks,
Francis
https://www.stockopedia.com/ac...
Thanks Phil, I signed up. With time difference it's difficult but I'll watch catchup on the Friday that should be okay.
https://newsfile.refinitiv.com...
Cogstate up 6% overnight ...
** Shares of Australia's CogState CGS.AX rise as much as 7.8% to A$2.64, their highest level since January 5, 2022
** Logs biggest intraday pct rise since September 15
** Biotech company sees FY26 first-half revenue to be around 18%-20% better than the pcp and will closely align with the revenue of A$29.1 million ($18.88 million) reported in FY25 second-half
** Stock is up 147.9% YTD, including the session's moves
Thank you, Chris. I always benefit from your Reports
Thanks Chris, Happy New year.